ReviewJournal of internal medicine2023
Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.
Review in Journal of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Clinical characteristics of pediatric tumor-induced osteomalacia: a systematic review and individual patient data analysis.Frontiers in endocrinology · 2026Pooled it
- Indications for the evaluation and supplementation of hypophosphatemia: an umbrella systematic review of reviews and guidelines.BMC medicine · 2025Pooled it
- A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia.Bone research · 2026Trial
- Multimodal Functional Imaging in Tumor-induced Osteomalacia:Molecular imaging and radionuclide therapy · 2026Article
- Late diagnosis of SLC34A3-related hereditary hypophosphatemic osteomalacia following a low-energy proximal humeral 4-part fracture.JBMR plus · 2026Article
- Beyond tumor tracing: physiological uptake of sympathetic ganglia on somatostatin receptor PET/CT - prevalence, patterns, and biological rationale.European journal of nuclear medicine and molecular imaging · 2026Article
- Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review.Calcified tissue international · 2026Review
- Precise localization of phosphaturic mesenchymal tumor causing tumor-induced osteomalacia: the value of dual-tracer imaging with ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT.EJNMMI reports · 2026Article
- Recent research progress on the etiology and pathogenesis of tumor-induced osteomalacia: A review.Journal of bone oncology · 2026Review
- Article
- Beyond DOTATATE: [European journal of nuclear medicine and molecular imaging · 2026Article
- A Case of Tumor-Induced Osteomalacia Masked by Parathyroid Carcinoma.Journal of clinical medicine · 2026Article
- Diagnostic Performance of Somatostatin Receptor-directed PET/CT for Tumor-induced Osteomalacia.Molecular imaging and biology · 2026Article
- Burosumab for X-linked Hypophosphataemia and Tumour-induced Osteomalacia in Adults.TouchREVIEWS in endocrinology · 2026Review
- Diffuse and Prolonged Bone Pain Revealing Tumor-Induced Osteomalacia: A Case Report.Clinical case reports · 2026Article
- Global perspectives on the burden and management of hypophosphataemic osteomalacia in adult patients: an International Osteoporosis Foundation (IOF) survey.Archives of osteoporosis · 2026Article
- Article
- A nomogram for predicting surgery outcome of tumor-induced osteomalacia: a case-control study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Surgical Treatment for Osteomalacia Induced by Causative Tumor in the Knee Joint Region: A Single-Center Retrospective Clinical Study Over 10 Years.Orthopaedic surgery · 2025Article
- Serum Phosphorus Is a Fast and Highly Sensitive Marker Predictive of a Complete Cure of Tumor-Induced Osteomalacia.Journal of clinical medicine · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 15 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Patients present with progressive bone pain, muscle weakness, and fragility fractures. TIO is characterized by hypophosphatemia, excess renal phosphate excretion, and low/inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.